Abstract
From the carbolithiation of 6-morpholino fulvene (3) and different lithiated nitrogen containing heterocycles (2-N-methylimidazolyl, 2-N-(N,N-dimethylamino)methyl-imidazolyl, and 2-N-methylindolyl), the corresponding lithium cyclopentadienide intermediate (4a-c) was formed. These three lithiated intermediates underwent a transmetallation reaction with TiCl4 resulting in morpholino-functionalised titanocenes 5a-c. When these titanocenes were tested against LLC-PK cells, the IC50 values obtained were of 24, 36, and 41 μM respectively. The most cytotoxic titanocene in this paper (5a) with an IC50 value of 24 μM is found to be almost ten times less cytotoxic than cis-platin, which showed an IC50 value of 3.3 μM when tested on the epithelial pig kidney LLC-PK cell line, and approximately 2 times less cytotoxic than its dimethylamino-functionalised analogue. Encouragingly however, the IC50 value obtained for titanocene 5a is approximately 100 times better than titanocene dichloride itself.
Keywords: Anti-cancer drugs, cis-platin, titanocene, fulvene, morpholino-functionalised metallocenes, nitrogen containing heteroaryl-substituted metallocenes, RCC, LLC-PK
Medicinal Chemistry
Title: Synthesis and Cytotoxicity Studies of New Morpholino-Functionalised and N-Heteroaryl-Substituted Titanocene Anticancer Drugs
Volume: 4 Issue: 2
Author(s): M. Tacke, M. Hogan, J. Claffey and C. Pampillon
Affiliation:
Keywords: Anti-cancer drugs, cis-platin, titanocene, fulvene, morpholino-functionalised metallocenes, nitrogen containing heteroaryl-substituted metallocenes, RCC, LLC-PK
Abstract: From the carbolithiation of 6-morpholino fulvene (3) and different lithiated nitrogen containing heterocycles (2-N-methylimidazolyl, 2-N-(N,N-dimethylamino)methyl-imidazolyl, and 2-N-methylindolyl), the corresponding lithium cyclopentadienide intermediate (4a-c) was formed. These three lithiated intermediates underwent a transmetallation reaction with TiCl4 resulting in morpholino-functionalised titanocenes 5a-c. When these titanocenes were tested against LLC-PK cells, the IC50 values obtained were of 24, 36, and 41 μM respectively. The most cytotoxic titanocene in this paper (5a) with an IC50 value of 24 μM is found to be almost ten times less cytotoxic than cis-platin, which showed an IC50 value of 3.3 μM when tested on the epithelial pig kidney LLC-PK cell line, and approximately 2 times less cytotoxic than its dimethylamino-functionalised analogue. Encouragingly however, the IC50 value obtained for titanocene 5a is approximately 100 times better than titanocene dichloride itself.
Export Options
About this article
Cite this article as:
Tacke M., Hogan M., Claffey J. and Pampillon C., Synthesis and Cytotoxicity Studies of New Morpholino-Functionalised and N-Heteroaryl-Substituted Titanocene Anticancer Drugs, Medicinal Chemistry 2008; 4 (2) . https://dx.doi.org/10.2174/157340608783789202
DOI https://dx.doi.org/10.2174/157340608783789202 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Pharmacologically Active Vanadium Species: Distribution in Biological Media and Interaction with Molecular Targets
Current Medicinal Chemistry The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS
Anti-Cancer Agents in Medicinal Chemistry The Glycogen Synthase Kinase-3 in the Regulation of Ion Channels and Cellular Carriers
Current Medicinal Chemistry Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design The Influence of Ca<sup>2+</sup> and Zn<sup>2+</sup> on the Amyloid Fibril Formation by β-Casein
Protein & Peptide Letters Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine Synthesis and Cytotoxic Activity of New β-Carboline Derivatives
Mini-Reviews in Medicinal Chemistry Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Androgen Metabolic Pathway Involved in Current and Emerging Treatment for Men with Castration Resistant Prostate Cancer: Intraprostatic Androgens as Therapeutic Targets and Endocrinological Biomarkers
Current Drug Targets From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Current Pharmaceutical Design